Placebo matching Ipilimumab

BIOLOGICAL2 trials

Conditions

MelanomaSmall Cell Lung Carcinoma

Phase 3

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

CompletedNCT01450761

Bristol-Myers SquibbSmall Cell Lung Carcinoma

Start: 2011-12-13End: 2017-05-17Updated: 2020-07-08

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

CompletedNCT02388906

Bristol-Myers SquibbMelanoma

Start: 2015-03-16End: 2024-10-16Updated: 2025-04-24

2025-10-182 citations

Abstract B027: Combining total cell-free DNA (cfDNA) and circulating tumor (ctDNA) to enhance the clinical sensitivity of ddPCR assays to detect minimal residual disease (MRD) in stage IIIB/C/IV melanoma patients on adjuvant immunotherapy in CheckMate 238

Clinical Cancer Research2024-11-13

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials

Journal of Clinical Oncology2024-10-084 citations

Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in Checkmate 238.

Journal of Clinical Oncology2023-06-015 citations

The validity of a machine learning algorithm in predicting response to immune checkpoint inhibitors in melanoma.

Journal of Clinical Oncology2023-06-011 citations

Determinants of racial disparities in immune-related adverse events (irAE) with checkpoint inhibition (ICI) in melanoma.

Journal of Clinical Oncology2023-06-01

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.

2022-08-1124 citations

Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.

2021-10-1515 citations

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

Journal for ImmunoTherapy of Cancer2021-08-0118 citations

Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data.

Journal of Clinical Oncology2021-05-206 citations

Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238.

Journal of Clinical Oncology2021-05-205 citations

TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma.

2020-12-0710 citations

308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma

Regular and Young Investigator Award Abstracts2020-11-011 citations

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.

2020-09-19368 citations

Abstract 2017: Association of digital and manual quantification of tumor PD-L1 expression with outcomes in nivolumab-treated patients

Cancer Research2020-08-155 citations

An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).

Journal of Clinical Oncology2019-05-207 citations

Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).

Journal of Clinical Oncology2018-05-2075 citations

Indirect treatment comparison of nivolumab versus placebo as an adjuvant therapy for resected melanoma.

Journal of Clinical Oncology2018-05-203 citations

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

New England Journal of Medicine2017-09-102146 citations

Placebo matching Ipilimumab

Sponsors

Conditions

Phase 3

Related Papers